Finch Therapeutics Group, Inc. Profile Avatar - Palmy Investing

Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that i…

Biotechnology
US, Somerville [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Finch Therapeutics Group, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of FNCH's Analysis
CIK: 1733257 CUSIP: 31773D101 ISIN: US31773D2009 LEI: - UEI: -
Secondary Listings
FNCH has no secondary listings inside our databases.